ArticleJournal of gastrointestinal oncology2025

Camrelizumab plus sorafenib or apatinib achieved long-term survival in a patient with hepatocellular carcinoma and an Eastern Cooperative Oncology Group performance status of 3: a case report.

Xin Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.